Christopher Moxham

Christopher Moxham has a diverse and extensive work experience in the pharmaceutical industry. Christopher is currently working at Rarebase as the Chief Executive Officer since October 2023, after briefly serving as the President from July to October 2023. Previously, at Fulcrum, they held the position of Chief Scientific Officer from January to November 2021, and prior to that, they were the Senior Vice President of Discovery Research from February 2019 to January 2021.

Christopher'searlier experience includes various roles at Eli Lilly and Company. As the Vice President of Quantitative Biology of Lilly NY, from 2015 to 2019, they oversaw the establishment and leadership of an in vitro pharmacology organization and the design of a new lab facility. Christopher also served as the Associate Vice President of Oncology Research Biomarkers, from 2012 to 2015, where they established a high-performing biomarker group to support the antibody drug conjugate molecules portfolio.

Before joining Eli Lilly, Moxham worked at Merck as a Senior Research Fellow and at Wyeth Ayerst Laboratories as a Sr. Research Scientist II. Christopher'searly roles at Eli Lilly included Head of Lead Generation Biology, Research Scientist/Platform Leader, and Research Scientist.

Overall, Christopher Moxham's work experience demonstrates their expertise in scientific research and leadership within the pharmaceutical industry.

Christopher Moxham holds a Ph.D. in Molecular and Cellular Pharmacology from Stony Brook University, obtained in 1993. Christopher also earned a Bachelor of Science degree in Biology from Cornell University in 1989.